← Leaderboards
Christopher A Benedict
La Jolla Institute For Immunology
$10,015,835
Attributed
$10,738,499
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,738,499 · 8
By mechanism
R01$7,873,046 · 2
R21$2,005,428 · 4
R56$860,025 · 2
Top collaborators
- Tatiana Hurtado De Mendoza2 shared
- Mitchell Kronenberg2 shared
- Jason W Upton2 shared
Most similar at La Jolla Institute For Immunology
Same institution · by research overlap
- Michael Croft$34,527,225
- Shahram Salek-Ardakani$2,121,581
- Alessandro Sette$107,498,738
- Dirk M Zajonc$4,071,502
Others in their field
Top investigators on “Immunity”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmunityViralCytomegalovirusMediatingCd4 Positive T LymphocytesCellsVirusHerpesviridaeCytomegalovirus InfectionsEpitopesImmune ResponseImmuneInfectionT Cell ResponseT-LymphocyteProteinsAntiviral AgentsMurid Herpesvirus 1Salivary GlandsImmune SystemEquilibriumCytokineImmune System DiseasesResponse
Grant awards (25)
Harnessing Cytomegalovirus (CMV)-specific T-cells for pancreatic cancer immunotherapy$190,283
R21 · FY2025 · CA
Harnessing Cytomegalovirus (CMV)-specific T-cells for pancreatic cancer immunotherapy$242,178
R21 · FY2024 · CA
CD4 T cell control of cytomegalovirus$565,653
R01 · FY2023 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$549,000
R01 · FY2023 · AI · contact PI
CD4 T cell control of cytomegalovirus$615,063
R01 · FY2022 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$549,000
R01 · FY2022 · AI · contact PI
CD4 T cell control of cytomegalovirus$615,063
R01 · FY2021 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$549,000
R01 · FY2021 · AI · contact PI
CD4 T cell control of cytomegalovirus$720,659
R01 · FY2020 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$549,000
R01 · FY2020 · AI · contact PI
CD4 T cell control of cytomegalovirus$720,659
R01 · FY2019 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$549,000
R01 · FY2019 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$442,500
R01 · FY2017 · AI · contact PI
Necroptosis and adaptive immunity to virus infection$215,537
R21 · FY2017 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$442,500
R01 · FY2016 · AI · contact PI
Necroptosis and adaptive immunity to virus infection$277,855
R21 · FY2016 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$442,500
R01 · FY2015 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$442,500
R01 · FY2014 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$120,949
R01 · FY2013 · AI · contact PI
The role of TRAIL in immune control of cytomegalovirus$435,000
R56 · FY2012 · AI · contact PI
Activation of NKT cells by cytomegalovirus$236,125
R21 · FY2010 · AI · contact PI
CMV UL144 targets the HVEM-BTLA cosignaling system$425,025
R56 · FY2009 · AI · contact PI
Activation of NKT cells by cytomegalovirus$283,350
R21 · FY2009 · AI · contact PI
Activation of innate antiviral defenses by LTbetaR$280,050
R21 · FY2005 · AI
Activation of innate antiviral defenses by LTbetaR$280,050
R21 · FY2004 · AI